Evelo Biosciences (NASDAQ:EVLO – Get Rating) had its target price cut by BMO Capital Markets from $10.00 to $5.00 in a research report issued on Friday, The Fly reports.
A number of other equities research analysts have also weighed in on EVLO. Morgan Stanley dropped their price objective on shares of Evelo Biosciences from $4.00 to $2.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 15th. Cantor Fitzgerald downgraded Evelo Biosciences from an “overweight” rating to a “neutral” rating in a research note on Thursday. Finally, Jefferies Financial Group cut Evelo Biosciences from a “buy” rating to an “underperform” rating in a research note on Wednesday, February 1st.
Evelo Biosciences Stock Down 13.4 %
NASDAQ:EVLO opened at $0.26 on Friday. The company has a current ratio of 2.69, a quick ratio of 2.69 and a debt-to-equity ratio of 3.93. Evelo Biosciences has a twelve month low of $0.26 and a twelve month high of $4.36. The company has a market cap of $27.95 million, a PE ratio of -0.18 and a beta of 1.37. The company’s 50 day moving average is $0.84 and its two-hundred day moving average is $1.59.
Hedge Funds Weigh In On Evelo Biosciences
Evelo Biosciences Company Profile
Evelo Biosciences, Inc operates as a clinical stage biotechnology company, which engages in the development of orally delivered investigational medicines. Its portfolio includes EDP1066 and EDP1815 for the treatment of inflammatory diseases, EDP2939 for inflammation, and EDP1908 for oncology. The company was founded by Noubar B.
- Get a free copy of the StockNews.com research report on Evelo Biosciences (EVLO)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Evelo Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evelo Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.